Allogeneic Cell Therapies

Natural Killer (NK) and T-cell therapies (CAR-T, TCR, TIL, T-Reg)

NK and T-cell therapies require specialized expertise process development, cell engineering, cell culture, and cell expansion. Lonza has extensive experience in the development and manufacture of NK and various T-cell therapies, including CAR-T, TCR, TIL, and Treg cells. We support multiple commercial and late-phase products across our network with a strong history of delivery, working with some of the pioneers in the allogeneic space. Our large, diverse and experienced team of scientists in process development has the expertise to choose the right technology for your product and demand, with a scale-appropriate model to start clinical trials early, aiding a smooth transition into a larger scale process, when the need comes.

Induced pluripotent stem cells (iPSCs)

iPSCs are a powerful tool for cell therapy development. Lonza is a pioneer in the development and manufacturing of iPSCs, including reprogramming, cell expansion and differentiation into various cell types: T-Cells, NK Cells, MSCs, Beta Cells, Neurons, Cardiomyocytes amongst others. We have the expertise to optimize iPSC culture conditions, ensure consistent cell quality, and optimize robust differentiation protocols. Our teams of scientists regularly publish research on advancements in the field of iPSC development, characterization and manufacturing. Furthermore, Lonza manufactured the world’s first reported GMP bank for the National Institute of Health (NIH).

Learn more

Mesenchymal stem cells (MSCs)

Lonza has been developing and manufacturing MSCs since the early 2000s, including tissue sourcing and cell banking, supporting multiple late-stage projects over the years. We have the expertise to optimize MSC culture conditions, ensure consistent cell quality, and develop robust and compliant 2D and 3D manufacturing processes for our customers. We are experts in industrial manufacturing of MSCs, having produced hundreds of GMP batches. We have developed and optimized an operational model that reduces Cost-of-Good (COGs) to serve large-scale, commercial demand.

Hematopoietic stem cells (HSCs)

Are a valuable source of cells for cell therapy and regenerative medicine, but their use can be limited by the availability of suitable donors and the challenges associated with HSC isolation, culture, and expansion. With hundreds of GMP batches produced, Lonza has extensive experience in the development and manufacture of HSCs, including tissue sourcing, cell isolation and expansion. We have the expertise to optimize HSC culture conditions, ensure consistent cell quality, and develop robust manufacturing processes.

Contact our experts